11 November 2026 | Curated by Gurdeep Singh, Amritsar, Punjab
Apollo Hospitals Enterprise has disclosed further details of its September-quarter performance and expansion plans in the earnings-call transcript filed with the stock exchanges on November 11. The update highlights a key milestone for its digital healthcare platform: Apollo 24/7 reported digital cash profit of ₹1 crore in Q2 FY27, compared with a digital cash loss of ₹39 crore in the corresponding quarter last year.
The company also outlined progress on hospital capacity expansion, including the commissioning of 520 beds from a planned 1,395 census-bed addition across FY2026–27. Management said the Gurugram hospital is expected to be commissioned before the next quarterly results update.
Apollo 24/7 reaches a cash-positive milestone
Apollo HealthCo, which houses the pharmacy and omnichannel digital healthcare businesses, reported Q2 FY27 revenue of ₹3,286 crore, up 23% year on year. Its EBITDA increased 75% to ₹193 crore, while profit after tax rose to ₹118 crore from ₹73 crore in the year-ago quarter.
Within this business, Apollo 24/7 recorded digital cash profit of ₹1 crore, compared with a loss of ₹39 crore in Q2 FY26. This is an important operating milestone for the platform after a period of investment in digital healthcare and online pharmacy services.
The distinction matters: the ₹1 crore figure is digital cash profit cited by management for Apollo 24/7. It should not be confused with the total profit of Apollo HealthCo, which reported ₹118 crore in quarterly PAT, or with the consolidated profit of Apollo Hospitals Enterprise.
Consolidated Q2 performance remains strong
Apollo Hospitals reported consolidated revenue of ₹7,615 crore in Q2 FY27, an increase of 23% year on year. Consolidated EBITDA rose 29% to ₹1,191 crore, with the EBITDA margin improving to 15.6% from 14.9% in Q2 FY26. Consolidated profit after tax increased 32% to ₹630 crore.
The healthcare services business generated revenue of ₹3,900 crore, up 23%. Inpatient volumes increased 14% year on year and hospital occupancy improved to 73%, compared with 69% in the year-ago quarter. Average revenue per patient rose 8% to ₹1,86,880.
Hospital expansion: 520 beds commissioned
Management reiterated the plan to add 1,395 census beds across FY2026–27. Of these, 520 beds had been commissioned by the time of the earnings call, while the remaining capacity is expected to be commissioned over the following 12–18 months.
The company said the Gurugram facility is expected to be commissioned before the next quarterly update. Management also referred to the rollout of hospitals in Pune, Kolkata, Hyderabad, Delhi, Sarjapur and Gurugram as part of the broader expansion programme.
New hospitals typically require time to build occupancy, recruit clinical teams and reach operating efficiency. Apollo said one of its newer hospitals in Hyderabad had already reached EBITDA breakeven, while three other new facilities were expected to reach breakeven by the end of the financial year, according to management’s comments on the call.
International patient business gains momentum
Apollo said international patient services revenue grew 37% year on year in Q2 FY27. The company attributed its broader healthcare services growth to higher patient volumes and demand for complex clinical procedures across specialties such as oncology, gastroenterology, cardiac care, orthopaedics and urology.
International patient growth is strategically relevant because it reflects demand from patients seeking specialised treatment in India. The company’s ability to maintain this momentum will depend on clinical capacity, service quality, international reach and competition from healthcare providers in other destinations.
What the transcript adds to the results announcement
The quarterly results released earlier established the headline financial performance. The November 11 transcript provides additional management commentary on the operating milestones behind those numbers: the digital cash-positive status of Apollo 24/7, the number of beds already commissioned, the expected timing of the Gurugram facility and the ramp-up outlook for newer hospitals.
Management also indicated that one-time scheme and integration-related expenses may continue into the second half of FY27 as the group progresses with the proposed restructuring of its omnichannel pharmacy and digital healthcare business. Investors should factor these comments into their assessment of near-term margins and the potential value-unlocking process.
What investors should watch next
Apollo 24/7: Whether the digital platform can sustain positive cash generation while expanding its customer and order base.
HealthCo performance: Revenue growth, EBITDA improvement and progress on the proposed restructuring and listing process.
Bed commissioning: The pace at which the remaining planned capacity becomes operational.
New-hospital breakeven: Occupancy, staffing, clinical mix and operating costs as recently opened facilities mature.
International patients: Whether the 37% revenue growth can be sustained over coming quarters.
The takeaway
Apollo Hospitals’ latest earnings-call transcript points to progress on two fronts: improving economics in its digital healthcare platform and continued expansion of its hospital network. Apollo 24/7’s ₹1 crore digital cash profit is a notable milestone, while the commissioning of 520 beds provides a measurable update on the company’s capacity programme.
The key test will be consistency. Investors will want to see whether Apollo 24/7 can maintain positive cash generation, whether new hospitals can reach planned utilisation and whether capacity expansion translates into sustainable margins and returns on capital.
This report is for news and information purposes only. It is not investment advice or a recommendation to buy, sell or hold Apollo Hospitals shares.
Like what you read? Help BoldVoices.in keep independent journalism going.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
